Over the course of 2018, the FDA approved 59 different novel drugs that range for the treatment of various cancers, chronic obstructive pulmonary disease (COPD), traveler’s diarrhea, migraine headaches and more.

The U.S. Food and Drug Administration approved Akcea Therapeutics’ rare genetic disease drug Tegsedi, which was developed along with Ionis Pharmaceuticals.

Alnylam Pharmaceuticals’ Onpattro won U.S. regulatory approval for a rare hereditary disease, becoming the first approved treatment from a new class of medicines that use gene silencing technology.